BALCHEM CORP

BCPC 10-K · FY 2025
API behind this page

BCPC FY 2025 request

Playground key active
Request URL /api/financials?ticker=BCPC&year=2025&quarter=4&full_year_mode=true
waiting 0 ms 
Pick an endpoint and run the request.
curl

Income Statement

JSON CSV Excel
Income Statement
Metric FY 2025 FY 2024 YoY
Revenue 1,037,161 953,684 +8.8%
Show Product Lines breakouts
Product Sales Revenue 1,035,272 951,947 +8.8%
Royalty 1,889 1,737 +8.8%
Show Business Segments breakouts
Animal Nutrition and Health · Operating Segments 230,852 214,710 +7.5%
Human Nutrition and Health · Operating Segments 659,387 600,258 +9.9%
Specialty Products · Operating Segments 140,976 132,749 +6.2%
Show Geography breakouts
Non Us 277,713 230,384 +20.5%
US 759,448 723,300 +5.0%
Show Consolidation Items breakouts
Corporate Non Segment 5,946 5,967 -0.4%
Cost of Revenue 666,528 617,478 +7.9%
Show Product Lines breakouts
Raw Materials Sold · Corporate Joint Venture 39,480 29,795 +32.5%
Service · Corporate Joint Venture 4,640 4,425 +4.9%
Show Business Segments breakouts
Animal Nutrition and Health · Operating Segments 180,292 171,409 +5.2%
Human Nutrition and Health · Operating Segments 415,102 378,411 +9.7%
Specialty Products · Operating Segments 63,611 59,449 +7.0%
Show Consolidation Items breakouts
Corporate Non Segment 7,523 8,209 -8.4%
Show Related Party Transactions By Related Party breakouts
Corporate Joint Venture 32,820 22,940 +43.1%
Gross Profit 370,633 336,206 +10.2%
Show Business Segments breakouts
Animal Nutrition and Health · Operating Segments 50,560 43,301 +16.8%
Human Nutrition and Health · Operating Segments 244,285 221,847 +10.1%
Specialty Products · Operating Segments 77,365 73,300 +5.5%
Show Consolidation Items breakouts
Corporate Non Segment -1,577 -2,242 +29.7%
Selling Expense 75,374 68,916 +9.4%
Research & Development 18,510 16,793 +10.2%
General & Administrative 67,423 67,588 -0.2%
Operating Expenses 161,307 153,297 +5.2%
Show Business Segments breakouts
Animal Nutrition and Health · Operating Segments 31,873 29,288 +8.8%
Human Nutrition and Health · Operating Segments 90,379 85,890 +5.2%
Specialty Products · Operating Segments 34,464 33,394 +3.2%
Show Consolidation Items breakouts
Corporate Non Segment 4,591 4,725 -2.8%
Operating Income 209,326 182,909 +14.4%
Show Business Segments breakouts
Animal Nutrition and Health · Operating Segments 18,687 14,013 +33.4%
Human Nutrition and Health · Operating Segments 153,906 135,957 +13.2%
Specialty Products · Operating Segments 42,901 39,906 +7.5%
Show Consolidation Items breakouts
Corporate Non Segment -6,168 -6,967 +11.5%
Interest Income Expense Nonoperating Net 10,219 16,528 -38.2%
Other Non-Operating Income (Expense) 77 -72 +206.9%
Non-Operating Income (Expense) 10,296 16,456 -37.4%
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments 199,030 166,453 +19.6%
Income Tax Expense (Benefit) 44,185 37,978 +16.3%
Net Income 154,845 128,475 +20.5%
Show Equity Components breakouts
Retained Earnings 154,845 128,475 +20.5%
EPS (Basic) 4.8 3.97 +20.9%
EPS (Diluted) 4.75 3.93 +20.9%
Comprehensive Income 220,139 96,037 +129.2%
Other Comprehensive Income 65,294 -32,438 +301.3%
Show Equity Components breakouts
Accumulated Defined Benefit Plans Adjustment -241 — —
Accumulated Other Comprehensive Income 65,294 -32,438 +301.3%
Accumulated Translation Adjustment 65,535 — —
Wtd Avg Shares (Basic) 32,265 32,332 -0.2%
Wtd Avg Shares (Diluted) 32,604 32,718 -0.3%
Income Loss From Equity Method Investments (FY) — — —
Show Schedule Of Equity Method Investment Equity Method Investee Name breakouts
St. Gabriel CC Company, LLC 491 489 +0.4%

Balance Sheet

Balance Sheet
Metric FY 2025 FY 2024 YoY
Current Assets
Cash & Cash Equivalents 74,570 49,515 +50.6%
Accounts Receivable 143,596 119,662 +20.0%
Show Related Party Transactions By Related Party breakouts
Corporate Joint Venture 4,225 3,893 +8.5%
Inventory 131,449 130,802 +0.5%
Other Prepaid Expense Current 9,778 8,054 +21.4%
Other Assets Current 6,221 5,737 +8.4%
Total Current Assets 365,614 313,770 +16.5%
Non-Current Assets
Property, Plant & Equipment 306,648 282,154 +8.7%
Goodwill 816,375 780,030 +4.7%
Show Business Segments breakouts
Animal Nutrition and Health · Operating Segments 24,912 23,974 +3.9%
Human Nutrition and Health · Operating Segments 706,515 678,275 +4.2%
Specialty Products · Operating Segments 84,899 77,732 +9.2%
Show Consolidation Items breakouts
Corporate Non Segment 49 49 0.0%
Intangible Assets 132,994 132,484 +0.4%
Operating Lease Right-of-Use Assets 14,672 15,320 -4.2%
Other Non-Current Assets 18,134 17,317 +4.7%
Total Assets 1,686,252 1,575,371 +7.0%
Show Business Segments breakouts
Animal Nutrition and Health · Operating Segments 176,608 161,243 +9.5%
Human Nutrition and Health · Operating Segments 1,243,522 1,185,962 +4.9%
Specialty Products · Operating Segments 172,076 161,283 +6.7%
Show Consolidation Items breakouts
Corporate Non Segment 94,046 66,883 +40.6%
Other Assets
Other Intangible Assets Net 30,295 32,566 -7.0%
Finance Lease Right Of Use Asset 1,520 1,730 -12.1%
Current Liabilities
Accounts Payable Trade Current 60,425 54,745 +10.4%
Show Related Party Transaction breakouts
Non-contractual monies owed · Corporate Joint Venture 296 296 0.0%
Show Related Party Transactions By Related Party breakouts
Corporate Joint Venture 3,369 2,831 +19.0%
Accrued Liabilities 49,288 43,750 +12.7%
Employee Related Liabilities Current 27,896 22,886 +21.9%
Dividends Payable Current 31,044 28,510 +8.9%
Taxes Payable Current 3,912 4,466 -12.4%
Operating Lease Liability Current 3,614 3,134 +15.3%
Finance Lease Liability Current 205 194 +5.7%
Total Current Liabilities 176,384 157,685 +11.9%
Non-Current Liabilities
Deferred Tax Liabilities 54,143 43,722 +23.8%
Operating Lease Liabilities 11,324 12,967 -12.7%
Finance Lease Liability Noncurrent 1,544 1,749 -11.7%
Other Long Term Debt Noncurrent 21,444 19,335 +10.9%
Total Liabilities 428,839 425,458 +0.8%
Other Liabilities
Long Term Line Of Credit 164,000 190,000 -13.7%
Stockholders' Equity
Common Stock 2,139 2,170 -1.4%
Additional Paid-In Capital 92,331 173,997 -46.9%
Retained Earnings 1,121,396 997,493 +12.4%
Accumulated Other Comprehensive Income 41,547 -23,747 +275.0%
Total Stockholders' Equity 1,257,413 1,149,913 +9.3%
Show Equity Components breakouts
Accumulated Defined Benefit Plans Adjustment 194 435 -55.4%
Accumulated Other Comprehensive Income 41,547 -23,747 +275.0%
Accumulated Translation Adjustment 41,353 -24,182 +271.0%
Additional Paid In Capital 92,331 173,997 -46.9%
Common Stock 2,139 2,170 -1.4%
Retained Earnings 1,121,396 997,493 +12.4%
Total Liabilities & Equity 1,686,252 1,575,371 +7.0%

Cash Flow Statement

Cash Flow Statement
Metric FY 2025 FY 2024 YoY
Operating Activities
Depreciation & Amortization 45,690 47,973 -4.8%
Show Business Segments breakouts
Animal Nutrition and Health · Operating Segments 7,282 8,233 -11.6%
Human Nutrition and Health · Operating Segments 30,119 31,668 -4.9%
Specialty Products · Operating Segments 7,365 7,044 +4.6%
Show Consolidation Items breakouts
Corporate Non Segment 924 1,028 -10.1%
Stock-Based Compensation 18,057 16,675 +8.3%
Deferred Income Taxes 6,262 -6,779 +192.4%
Provision For Doubtful Accounts -97 299 -132.4%
Unrealized Gain Loss On Foreign Currency Transactions And Deferred Compensation -680 -100 -580.0%
Gain Loss On Sales Of Assets And Asset Impairment Charges -58 1,664 -103.5%
Change in Accounts Receivable -20,853 5,582 -473.6%
Change in Inventory 3,635 -22,791 +115.9%
Change in Prepaid & Other Assets -1,332 225 -692.0%
Increase Decrease In Accounts Payable And Accrued Liabilities 11,292 9,065 +24.6%
Increase Decrease In Accrued Income Taxes Payable -1,070 -583 -83.5%
Other Operating Activities Cash Flow Statement 865 2,385 -63.7%
Net Cash from Operations 216,556 181,999 +19.0%
Investing Activities
Payments To Acquire Other Productive Assets -43,489 -35,661 -22.0%
Payments To Acquire Businesses Net Of Cash Acquired -323 -24,164 +98.7%
Proceeds From Sale Of Property Plant And Equipment 274 359 -23.7%
Payments To Acquire Interest In Subsidiaries And Affiliates -353 -270 -30.7%
Net Cash from Investing -43,891 -59,736 +26.5%
Financing Activities
Proceeds From Lines Of Credit 88,000 26,000 +238.5%
Repayments Of Long Term Lines Of Credit -114,000 -145,569 +21.7%
Finance Lease Principal Payments -194 -216 +10.2%
Proceeds From Stock Options Exercised 9,307 17,228 -46.0%
Payments Of Dividends -28,287 -25,576 -10.6%
Share Repurchases -107,636 -5,682 -1794.3%
Net Cash from Financing -152,810 -133,815 -14.2%
Amortization of Financing Costs 288 287 +0.3%
Supplemental
Income Taxes Paid 37,749 42,643 -11.5%
Interest Paid 10,603 17,697 -40.1%
Other Cash Flow
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 5,200 -3,380 +253.8%
Net Change in Cash 25,055 -14,932 +267.8%
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 74,570 49,515 +50.6%

Values in thousands USD. Source: SEC EDGAR 10-K filing.

This table is rendered from the same JSON returned by /api/financials.

Get API Key